Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment

Molecular Imaging and Biology

Volumn 12, Issue 2, 2010, Pages 210-217

  Richter, José A ^a   Rodríguez, Macarena ^a   Rioja, Jorge ^a   Peñuelas, Iván ^a   Martí Climent, Josep ^a   Garrastachu, Puy ^a   Quincoces, Gemma ^a   Zudaire, Javier ^a   García Velloso, María J ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

11C choline; Early detection; FDG; PET; Prostate cancer; PSA; Relapse

Indexed keywords

ANTIANDROGEN; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; PROSTATE SPECIFIC ANTIGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BIOCHEMISTRY; CANCER RADIOTHERAPY; CANCER RELAPSE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; GLEASON SCORE; HORMONAL THERAPY; HUMAN; IMAGE ANALYSIS; IMAGE RECONSTRUCTION; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY; BLOOD; MIDDLE AGED; PROSTATE TUMOR; SCINTISCANNING; TUMOR RECURRENCE;

ADULT; AGED; CARBON RADIOISOTOPES; CHOLINE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77953535309     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-009-0243-y     Document Type: Article

References (38)

1. Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270(8):948-954
2. Moul JW (1998) Treatments options for prostate cancer: part1-stage, grade, PSA and changes in the 1990s. Am J Manag Care 4:1031
3. Ravery V (1999) The significance of recurrent PSA after radical prostatectomy: benign versus malignant sources. Semin Urol Oncol 17 (3):127-129
4. Consensus statement: guidelines for PSA following radiation therapy (1997) American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 37:1035-1041
5. Partin AW, Pearson JD, Landis PK et al (1994) Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43(5):649-659
6. Moul JW (2000) Prostate specific antigen only progression of prostate cancer. J Urol 163(6):1632-1642
7. Coakley FV, Teh HS, Qayyum A, Swanson MG et al (2004) Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 233(2):441-448
8. 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 84(9):1028-1031
9. Jeong HJ, Min JJ, Park JM et al (2002) Determination of the prognostic value of [(18) F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 23(9):865-870
10. 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 43(1):46-55
11. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med 44(4):549-555
12. Hara T, Kosaka N, Kishi H (1998) PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 39(6):990-995
13. Breeuwsma AJ, Pruim J, Jongen MM et al (2005) In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer. Eur J Nucl Med Mol Imaging 32(6):668-673
14. Van Laere K, Ceyssens S, Van Calenbergh F et al (2005) Direct comparison of 18F-FDG and 11C-methionine PET in suspected recurrence of glioma: sensitivity, inter-observer variability and prognostic value. Eur J Nucl Med Mol Imaging 32(1):39-51
15. Richter JA, Rodriguez M, Martinez Monge R et al (2005) Value of PET18FDG and 11C-choline in the early diagnosis of relapse in prostate cancer. J Nucl Med 46:98P [abstract]
16. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281(17):1591-1597
17. Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T et al (2004) Management of prostate-specific antigen relapse in prostate cancer: a European consensus. Int J Clin Pract 58:382-390
18. Moul JW (2003) Biochemical recurrence of prostate cancer. Curr Probl Cancer 27(5):243-272
19. Peñuelas I, Martí-Climent JM, García-Velloso MJ, Rodríguez-Fraile M, Richter JA (2003) Automatización de la síntesis en fase sólida y la purificación de (N-metil[11C])colina. Rev Esp Med Nuclear 22(3):163 [abstract]
20. Picchio M, Messa C, Landoni C et al (2003) Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 169(4):1337-1340
21. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ (2003) 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 44(1):32-38
22. Krause BJ, Souvatzoglou M, Tuncel M et al (2008) The detection rate of [(11) C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 35(1):18-23
23. Reske SN, Blumstein NM, Glatting G (2008) [(11) C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 35(1):9-17
24. Rinnab L, Mottaghy FM, Blumstein NM et al (2007) Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 100(4):786-793
25. Husarik DB, Miralbell R, Dubs M, John H et al (2008) Evaluation of [(18) F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 35(2):253-263
26. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 165(4):1146-1151
27. Freedland SJ, Sutter ME, Dorey F, Aronson WJ (2003) Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 61(2):365-369
28. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH (2003) Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95 (18):1376-1383
29. Vees H, Buchegger F, Albrecht S et al (2007) 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 99(6):1415-1420
30. Heinisch M, Dirisamer A, Loidl W et al (2006) Positron emission tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA >5 ng/ml? Mol Imaging Biol 8(1):43-48
31. Coleman R, DeGrado T, Wang S et al (2000) Preliminary evaluation of F-18 fluorocholine (FCH) as a PET tumor imaging agent. Clin Positron Imaging 3(4):147 [Abstract]
32. Kubota K, Kubota R, Yamada S (1993) FDG accumulation in tumor tissue. J Nucl Med 34(3):419-421
33. Minn H, Joensuu H, Ahonen A, Klemi P (1988) Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 61(9):1776-1781
34. Gheiler EL, Tefilli MV, Tiguert R et al (1998) Predictors for maximal outcome in patients undergoing salvage surgery for radio-recurrent prostate cancer. Urology 51(5):789-795
35. Pucar D, Sella T, Schöder H (2008) The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery. Curr Opin Urol 18(1):87-97
36. Leventis AK, Shariat SF, Slawin KM (2001) Local recurrence after radical prostatectomy: correlation of US features with prostatic fossa biopsy findings. Radiology 219(2):432-439
37. Albertsen PC, Hanley JA, Harlan LC et al (2000) The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer: a population based analysis. J Urol 163(4):1138-1143
38. Sella T, Schwartz LH, Swindle PW et al (2004) Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology 231(2):379-385